Volume 48, Number 12, 887-892, DOI: 10.1007/s00234-006-0142-8

Tumor lysis syndrome as a contributory factor to the development of reversible posterior leukoencephalopathy

A. Ozkan, B. Hakyemez, F. Ozkalemkas, R. Ali, V. Ozkocaman, T. Ozcelik, O. Taskapilioglu, Y. Altundal and A. Tunali

View Related Documents

Abstract

Introduction  

Reversible posterior leukoencephalopathy syndrome (RPLS) is a recently described clinical and radiological entity comprising headache, seizures, altered level of consciousness and visual disturbances in association with transient posterior cerebral white-matter abnormalities.

Method  

We report a young woman with Burkitt’s lymphoma who developed RPLS after combined chemotherapy administered during the tumor lysis syndrome.

Results  

The symptoms in this patient fitted well with those of RPLS; they included abrupt alterations in mental status, seizures, headache, visual changes and characteristic neuroradiological findings. She was given further combination chemotherapy without any neurological complications, at which time she had already recovered from both RPLS and tumor lysis syndrome.

Conclusion  

Although many etiological factors have been reported in the development of RPLS, the underlying mechanism is not yet well understood. With prompt and appropriate management, RPLS is usually reversible, and chemotherapy can be continued after complete recovery from RPLS. We suggest that tumor lysis syndrome should be considered as a contributory factor to the development of RPLS in patients for whom treatment with combined chemotherapy for hematological malignancies is planned.

Keywords  Reversible posterior leukoencephalopathy syndrome - Tumor lysis syndrome - Chemotherapy - MRI

Fulltext Preview

Image of the first page of the fulltext document